menu
    • menu
    [{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Pharmadrug Production GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Cepharanthine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairiyo Therapeutics \/ Pharmadrug Production GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Sairiyo Therapeutics \/ Pharmadrug Production GmbH"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ Bayer AG"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ Fusion Pharma","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ Fusion Pharma"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"TRIUMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"n.c.a 225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ TRIUMF","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ TRIUMF"},{"orgOrder":0,"company":"Kinectrics","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ytterbium-176","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kinectrics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinectrics \/ Point Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Kinectrics \/ Point Biopharma"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BWX Technologies

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            BWX Technologies

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Fusion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            BWXT Medical Expands Collaboration with Fusion Pharmaceuticals through Strengthened Actinium Supply and Access...

                            Details : Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            November 16, 2023

                            Lead Product(s) : 225-Ac

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Fusion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genevant Sciences

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Genevant Sciences

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Gritstone bio

                            Deal Size : $136.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Gritstone bio and Genevant Sciences Announce Option and License Agreement

                            Details : Under the agreement, Gritstone will have a multi-year option for a non-exclusive license under Genevant’s LNP technology on a pathogen-by-pathogen basis to develop and commercialize self-amplifying RNA (samRNA) vaccines.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 15, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Gritstone bio

                            Deal Size : $136.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BWX Technologies

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            BWX Technologies

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products

                            Details : Under the terms of the commercial agreement, Bayer will purchase high-purity Ac-225 from BWXT Medical at pre-determined prices. Ac-225 is a highly powerful radioisotope used in targeted alpha therapies (TATs).

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            June 27, 2022

                            Lead Product(s) : 225-Ac

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BWX Technologies

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            BWX Technologies

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a 225-Ac

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : TRIUMF

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            TRIUMF and BWXT Medical Execute Agreement for Manufacture of Ac-225 Based Products

                            Details : TRIUMF will irradiate thorium-232 targets for BWXT Medical. From this irradiated thorium, BWXT Medical will process and produce high purity n.c.a Ac-225, sometimes referred to as non-carrier-added Ac-225, for commercial sale, strengthening BWXT Medicalâ€...

                            Product Name : n.c.a 225-Ac

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 13, 2022

                            Lead Product(s) : n.c.a 225-Ac

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : TRIUMF

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kinectrics

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Kinectrics

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ytterbium-176

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. L...

                            Details : With this agreement with Kinectrics, POINT to access large quantities of highly enriched Yb-176, creating the world’s first, stable North American supply of n.c.a. Lu-177, thereby establishing POINT as a dependable provider of high-quality radiopharmac...

                            Product Name : Yb-176

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 29, 2021

                            Lead Product(s) : Ytterbium-176

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sairiyo Therapeutics

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Sairiyo Therapeutics

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cepharanthine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Pharmadrug Production GmbH

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            PharmaDrug Enters Definitive Agreement to Acquire Sairiyo Therapeutics

                            Details : Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 25, 2021

                            Lead Product(s) : Cepharanthine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Pharmadrug Production GmbH

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth